secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001628280-23-028189
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma Q2 net loss $63.9M, no revenue, cash $632.7M; Phase 1 data on track
--------------------------------------------------------------------------------

- Net loss of $63.9M for Q2 2023, compared to $36.3M in Q2 2022; non-GAAP net loss $45.6M vs $10.3M.
- Revenue near zero vs $35.7M in prior year period, due to termination of GSK collaboration in Dec 2022.
- Cash, cash equivalents and marketable securities $632.7M as of June 30, 2023; expected to fund operations into 2026.
- Appointed Matt Lang as Chief Business Officer, also serving as Chief Legal Officer and Corporate Secretary.
- Phase 1 trials LYL797 and LYL845 ongoing; initial data expected 2024; IND for LYL119 expected H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828023028189/0001628280-23-028189-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828023028189/lyel-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-028189

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer